Finanzen von Spruce Biosciences, Inc (SPRB)SPRBSpruce Biosciences, Inc

Evaluating the bottom line, Spruce Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -105.98%, provide a clear picture of how effectively SPRB converts its operational activities into shareholder value.

In the context of the broader market, SPRB competes directly with industry leaders such as FHTX and HURA. With a market capitalization of $122.58M, it holds a leading position in the sector. When comparing efficiency, SPRB's gross margin of N/A stands against FHTX's 100.00% and HURA's N/A. Such benchmarking helps identify whether Spruce Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Spruce Biosciences has shown a gross margin of 100% in its latest quarter, but total revenue has been minimal, with $697,000 reported in Q4 2024 and no revenue in subsequent quarters, indicating a reliance on future product approvals for financial performance.